Anti-cyclic citrullinated peptide antibody is a specific autoantibody with high sensitivity and specificity for rheumatoid arthritis. Anti-cyclic citrullinated peptide antibodies greater than 200 RU/ml indicate that the patient may have rheumatoid arthritis and requires treatment for rheumatoid arthritis.
The normal range of anti-cyclic citrullinated peptide antibody is 0-5U/ml. The level of anti-cyclic citrullinated peptide antibody has a direct impact on the prognosis of rheumatoid arthritis, and anti-cyclic citrullinated peptide antibody greater than 200RU/ml indicates that the prognosis is poor, and the patient needs to be treated aggressively.
Drugs used to treat rheumatoid arthritis include non-steroidal anti-inflammatory drugs such as diclofenac, immunosuppressants such as methotrexate, biologics such as infliximab, and botanicals such as tretinoin. Surgery is also available to treat rheumatoid arthritis patients with severe joint dysfunction.
It is recommended that patients with anti-cyclic citrullinated peptide antibodies greater than 200RU/m should seek medical attention in time and follow the doctor’s instructions for standardized treatment.